Sultanate of Oman
Ministry of Health
Directorate General of Pharmaceutical
Affairs and Drug Control
Muscat

سلطنة عُمان
وزارة الصحة
المديرية العامة للصيدلة
والرقابة الدوائية
مسقط

To:
THE DIRECTOR GENERAL OF HEALTH SERVICES IN ALL GOVERNORATES
Commanding Officer, Armed Forces Hospital (Al Khoudh & Salalah)
Director General of Engineering Affairs, MOH
Director General of Royal Hospital
Director General of Khoula Hospital
Director General of Medical Supplies (MOH)
Director General of Pvt. Health Est. Affairs (to kindly arrange distribution to all Pvt. Hospitals)
Hospital Director (Al Nahda Hospital)
Hospital Director (Al Massara Hospital)
The Head of Medical Services in SQU Hospital
The Head of Medical Services in Royal Oman Police
The Head of Medical Services in Ministry of Defence
The Head of Medical Services in The Diwan
The Head of Medical Services in The Sultan's Special Force
The Head of Medical Services in Internal Security Services
The Head of Medical Services in Petroleum Development of Oman
The Head of Medical Services in LNG Oman
ALL PRIVATE PHARMACIES & DRUG STORES

After Compliments,

Please find attached our Circular No 213 **dated** 22/11/22 **Regarding NCMDR recall of A-CP Kits Family, RegenKit-BCT Family from (mfr: Regen Lab SA).**

Copy to:

- **Director, Office of H.E. The Undersecretary for Health Affairs**
- **Director of Medical Device Control, DGPA&DC**
- **Director of Pharmacovigilance & Drug Information Dept, DGPA&DC**
- **Director of Drug Control Department, DGPA&DC**
- **Director of Pharmaceutical Licensing Department, DGPA&DC**
- **Director of Central Quality Control Lab., DGPA&DC**
- **Supdt. of Central Drug Information**

PADC
المديرية العامة للصيدلة والرقابة الدوائية
Directorate General of Pharmaceutical Affairs & Drug Control
ISO 9001:2015 CERTIFIED

ص.ب: ٣٩٣ مسقط – الرمز البريدي: ١٠٠ – هاتف: ٢٢٣٥٧١١١ – فاكس: ٢٢٣٥٨٤٨٩
P.O. Box: 393 Muscat - Postal Code : 100 - Tel: 22357111 - Fax: 22358489
dgpa_dc Email: dg-padc@moh.gov.om

Sultanate of Oman
Ministry of Health
Directorate General of Pharmaceutical Affairs and Drug Control
Muscat

سلطنة عُمان
وزارة الصحة
المديرية العامة للصيدلة والرقابة الدوائية
مسقط

Circular No. 213 / 2022

28 -04-1444 H

22 -11-2022

Recall of A-CP Kits Family, RegenKit-BCT Family from Regen Lab SA

Source	NCMDR- National Center for Medical Devices Reporting- SFDA https://ncmdr.sfda.gov.sa/Secure/CA/CaViewRecall.aspx?caid=6&rid=17321
Product	A-CP Kits Family, RegenKit-BCT Family.
Description	Injections / Infusions / Transfusions / Dialysis - equipment for collecting blood products and peripheral stem cells.
Manufacturer	Regen Lab SA.
The affected products	Refer to "Details on Affected devices" in the attached FSN.
Reason	Inflammatory reaction after Platelet-Rich Plasma (PRP) injection characterized by pain and/or joint effusion.
Action	1. Please immediately stop using and quarantine all affected products. 2. Contact the local agent for remedial action.
comments	Healthcare professionals are encouraged to report any adverse events Suspected to be associated with the above device or any other medical device to Department of Medical Device Control through the E-mail: Med-device@moh.gov.om

Dr. Mohammed Hamdan Al Rubaie

Director General

PADC
المديرية العامة للصيدلة والرقابة الدوائية
Directorate General of Pharmaceutical Affairs & Drug Control

ص.ب: ٣٩٣ مسقط – الرمز البريدي: ١٠٠ – هاتف: ٢٢٣٥٧١١١ – فاكس: ٢٢٣٥٨٤٨٩
P.O. Box: 393 Muscat - Postal Code : 100 - Tel: 22357111 - Fax: 22358489
dgpa_dc Email: dg-padc@moh.gov.om

Formulaire de notice d'information de sécurité (field Safety Notice)

Details on affected devices:
Are concerned by this quarantine specific product codes of class IIb devices:

Product Code	Lot Number
A-CP-3	059
A-CP-3 USA	031 032 033 034 036 037 038 039 040 041 042 043 044 048 050 051 053 054 055
A-CP-3-20	047
R-ACR C/BA	141 142
R-ACR C2/B	138 139
RK-BCT-1	086 087
RK-BCT-1 USA	085
RK-BCT-2A	030
RK-BCT-3	301 302 303 305 306 307 308 309 310 311
RK-BCT-3 USA	300 304
RK-BCT-T	015

Formulaire de notice d'information de sécurité (field Safety Notice)

Description of the problem:

At the beginning of May 2022, French customers have reported several cases of patient's inflammatory reaction after Platelet-Rich Plasma (PRP) injection characterized by pain and/or joint effusion. Transient inflammatory reaction is identified as expected undesirable side-effects of the PRP injection as mentioned in our risk analysis and clinical report evaluation. These cases have only been reported following an intra-articular injection into the knee, and have generally resolved spontaneously, or have required medical treatment in several case. The analysis of the synovial fluid did not reveal any infection.

The medical follow-up of the patients stops when the inflammatory reaction due to the injection of PRP disappears, there is no need for additional follow-up. No particular follow-up is necessary for patients without inflammatory reaction following an injection of PRP.

From systematic literature searches conducted to identify all published data pertaining to RegenKits, it was found that side effects associated with the use of PRP for a large variety of medical use were minor and were of short duration. These reactions were of mild to moderate severity, localized to the treated area, transient, resolved spontaneously, or required the intake of medical treatment. Globally, when risks of use of PRP and other plasma-derived products prepared with RegenKits are compared to other conventional treatments according to the medical use, the use of RegenPRP is still associated with a lower risk profile.

The incriminated lots of tubes have been investigated. Some particles in the sodium citrate solution, with an irregular appearance of the separator gel and the presence of a white layer on the surface of the gel have been observed. (Note: the separator gel is used for the blood separation, it makes a physical barrier between the red blood cells and the Platelet Rich Plasma. Only the plasma is reinjected to the patient, the gel is not).

An investigation on concerned tubes was performed on this potential degradation of the gel.

After an internal investigation led with manufacturing documentation and reference samples, this issue seems to be due to a combination of factors during manufacturing.
If one of these factors is absent, the visual defect does not appear, suggesting this combination to be the contributory cause of the visual defect on the separator gel, and, consequently, to the patient's inflammatory reaction. The first reported customer complaints involve RK-BCT-3, batch number 302, manufactured in January 2022. Before January 2022, this combination was not used for BCT references.

Regen Lab continues to actively monitor the affected products to confirm the level of severity and of frequency, namely if those inflammatory reactions resolve spontaneously or require the intake of medical treatment. Moreover, several tests, internal and external, to investigate the root cause of this visual anomaly have been performed.

Regen Lab takes place a quarantine of products and batch numbers which have the suspected defective combination (see table above). More instructions will be communicated in the future.

Formulaire de notice d'information de sécurité (field Safety Notice)

Product Identification Procedure:
For a quarantine, the only way to identify affected products is by comparing product code and batch number to the quarantine product list (see table above).
See Annex 1 for example of package labeling that highlights the location of the product code and batch number on the device label which is located on the primary packaging. The product code (reference number) is preceded by the word "REF" and the batch number is preceded by word "LOT".

Advise on action to be taken by the distributor/user:
Our traceability shows that you have taken delivery of affected product. Please follow the steps below according to whether you are a distributor or an end-user in order to quarantine the affected product:

Actions to be taken by the distributor	Action to be taken by the end-user
1. *Please **immediately stop distributing** and quarantine all affected products.*	1. *Please **immediately stop using** and quarantine all affected products.*
2. *Please complete and return the "Quarantine Response Form for Distributors" (page 6) **no later than August 24th 2022** to Mr. Jean-Baptiste Pignier (jpignier@regenlab.com) and Mr. Baptiste Laroche (blaroche@regenlab.com)*	2. *Please fill and return to your distributor the "Quarantine Response Form for End-Users" (page 7) **no later than August 31th 2022** to Mr. Jean-Baptiste Pignier (jpignier@regenlab.com) and Mr. Baptiste Laroche (blaroche@regenlab.com)*
3. *Inform and send the FSN to end-users **no later than August 24th 2022**. They must fill and return to you the "Quarantine Response Form for End-Users" (page 7). You must then return to Regen Lab the end-user FSN form **no later than August 31th 2022** to Mr. Jean-Baptiste Pignier (jpignier@regenlab.com) and Mr. Baptiste Laroche (blaroche@regenlab.com)*	3. *Quarantined products will be progressively replaced by Regen Lab SA.*
4. *Your Regional contact will advise on suitable replacement stock.*	4. *Your Regional contact or Distributor will advise on suitable replacement stock.*

Thank you for your business and continued support. We sincerely apologize for any disruption this situation may cause to your organization.

Formulaire de notice d'information de sécurité (field Safety Notice)

If you have any questions about these actions, please do not hesitate to contact:

- **For Sales and Logistic queries**
  - Mr. Alain Lecompte, alecompte@regenlab.com
- **For queries related to batch quarantine**
  - Mr. Baptiste Laroche, QA/RA Manager, blaroche@regenlab.com
  - Mr. Jean-Baptiste Pignier, PMS Manager, jpignier@regenlab.com

REGEN LAB SA
En Budron B2,
CH-1052 Le Mont-sur-Lausanne,
Switzerland
Tel. +41 21 864 0111
Fax +41 21 864 0110

The undersigns confirm that this notice has been notified to the appropriate Regulatory Agencies.

	QA/RA Manager	PMS Manager
Full name and signature	Baptiste Laroche DocuSigned by: [redacted] Nom du signataire : Baptiste Laroche Motif de la signature : J'approuve ce document Heure de signature : 17 août 2022 | 11:03:51 AM CEST D3A7483D2A9C487380E76CEA650879F9	Jean-Baptiste Pignier DocuSigned by: [redacted] Nom du signataire : Jean-Baptiste Pignier Motif de la signature : J'approuve ce document Heure de signature : 17 août 2022 | 11:06:18 AM CEST 6EF3C675236445C5B41637956736OC11

Formulaire de notice d'information de sécurité (field Safety Notice)

Annex 1: Examples of Product Labelling

Labeling printed on Tyvek



Label on the folding box



Formulaire de notice d'information de sécurité (field Safety Notice)

Field Safety Notice

Commercial name of the affected products:

Family	Device Name	Reference
A-CP Kits Family	A-CP-Kit-3	A-CP-3
	A-CP-Kit-3	A-CP-3 USA
	A-CP-Kit-3 (20ml)	A-CP-3-20
RegenKit-BCT Family	RegenACR-C Plus	R-ACR C/BA
	RegenACR-C Extra	R-ACR C2/B
	RegenKit-BCT-1	RK-BCT-1
	RegenKit-BCT-1	RK-BCT-1 USA
	RegenKit-BCT-2 Plus	RK-BCT-2A
	RegenKit-BCT-3	RK-BCT-3
	RegenKit-BCT-3	RK-BCT-3 USA
	RegenKit-BCT-T	RK-BCT-T

FSCA-identifier FSCA-2022-05-16-A

Type of action *Product quarantine*

Please note that this action only applies to specific product codes and does not affect all product codes and LOTs of Regen Lab products.

Date: August 2nd 2022

Attention to: *QA Responsibles, Warehouse Managers, Physicians, Hospitals, Clinics, Pharmacists and Healthcare professionals who received the concerned products.*

This notice should be forwarded to all those who need to be aware of it within your organization and to maintain the awareness over the appropriate defined period.